Palvella Therapeutics, Inc. Additional Paid in Capital, Preferred Stock
Palvella Therapeutics, Inc. (PVLA) had Additional Paid in Capital, Preferred Stock of $22.75 thousand as of 2014-09-30, per its 10-Q filed 2014-11-13.
Discontinued › Balance Sheet › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalPreferredStock · last filed 2014-11-13
- 2014-09-30: Additional Paid in Capital, Preferred Stock $22.75K.
- 2014-06-30: Additional Paid in Capital, Preferred Stock $19.90K.
- 2014-03-31: Additional Paid in Capital, Preferred Stock $0.00.
- 2013-06-30: Additional Paid in Capital, Preferred Stock $0.00.
| Period end | Additional Paid in Capital, Preferred Stock |
|---|---|
| 2014-09-30 | $22.75K 10-Q · filed 2014-11-13 |
| 2014-06-30 | $19.90K 10-Q · filed 2014-11-13 |
| 2014-03-31 | $0.00 10-Q · filed 2014-06-02 |
| 2013-06-30 | $0.00 10-K · filed 2014-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |